Z
Zhejiang Taimei Medical Technology
A cloud platform for clinical research collaboration
About Zhejiang Taimei Medical Technology
Zhejiang Taimei Medical Technology Co., Ltd. operates as a digital solutions provider for the life science industry, with a strategic focus on the pharmaceutical and medical device sectors in China. Founded by Zhao Lu in June 2013, the company aims to enhance the research and development (R&D) and commercialization processes for its clients. Zhao Lu, who serves as the company's chairman, is the largest shareholder.
Taimei Technology's business model is centered on providing cloud-based, software-as-a-service (SaaS) products, eliminating the need for clients to install and maintain software on-premise. The company generates revenue through the sale of these self-developed SaaS products and by offering related professional services in the fields of clinical research, pharmacovigilance, and pharmaceutical marketing. Its clientele includes pharmaceutical companies, contract research organizations (CROs), and research institutes. By March 2024, Taimei had served over 1,400 pharmaceutical firms and CROs, including 21 of the top 25 global pharmaceutical companies.
The company's core offering is its TrialOS platform, a digital collaboration hub designed to connect key industry stakeholders such as pharmaceutical companies, hospitals, service providers, regulatory bodies, and patients. This platform facilitates data exchange and process cooperation by leveraging artificial intelligence, big data, and mobile internet technologies. In addition to TrialOS, the company offers PharmaOS, a digital marketing platform that integrates omnichannel marketing systems to provide data-driven solutions for sales management and customer targeting. Taimei also provides over 40 distinct software products and digital services, including solutions for clinical trial management, data collection and analysis, and pharmacovigilance. These offerings support the entire drug product lifecycle, from R&D to post-market activities.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2024
News
Open roles
Zhejiang Taimei Medical Technology in the Huangpu ecosystem
The Zhejiang Taimei Medical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Matrix Partners China
NLVC
Cowin Venture
Series B and later11 investors entered at this stage
Genesis Capital
SB China Capital
SAIF Partners- ZCZheshang Venture Capital
- ICIvy Capital
5Y Capital
Tiger Global
Tencent
GL Ventures
YunFeng Capital
Hillhouse Capital
Source: Dealroom Talent Intelligence.
Patents
230 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Zhejiang Taimei Medical Technology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

